SpringWorks Therapeutics Inc (SWTX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Saqib Islam
Employees:
180
100 WASHINGTON BOULEVARD, STAMFORD, CT 06902
203-883-9490

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.

Data derived from most recent annual or quarterly report
Market Cap 1.41 Billion Shares Outstanding49.414 Million Avg 30-day Volume 1.08 Million
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue0.0 Debt to Equity0.0 EBITDA-400.407 Million
Price to Book Value3.7087 Operating Margin0.0 Enterprise Value867.244 Million
Current Ratio9.796 EPS Growth0 Quick Ratio9.582
1 Yr BETA 1.3455 52-week High/Low 77.7 / 13.6 Profit Margin0.0
Operating Cash Flow Growth-196.6941 Altman Z-Score13.8099 Free Cash Flow to Firm -158.206 Million
Earnings Report2022-11-03
View SEC Filings from SWTX instead.

View recent insider trading info

Funds Holding SWTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SWTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-09-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-12:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-20:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-24:
    Item 2.02: Results of Operations and Financial Condition
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    428.5 Thousand total shares from 4 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    • 10% Owner
    5,599,842 2022-09-12 2

    SMITH L. MARY CHIEF DEVELOPMENT OFFICER

    • Officer
    193,076 2022-07-18 6

    BURGESS MICHAEL F. HEAD OF RESEARCH & DEVELOPMENT

    • Officer
    49,584 2022-07-18 3

    ALBAN CARLOS

    • Director
    40,218 2022-07-14 2

    LYNCH DANIEL

    • Director
    312,519 2022-05-19 1

    SQUINTO STEPHEN P

    • Director
    • 10% Owner
    6,333,277 2022-05-19 1

    FUHRMAN ALAN

    • Director
    21,242 2022-05-19 1

    LEWIS-HALL FREDA C

    • Director
    21,242 2022-05-19 1

    HAMBLETON JULIE

    • Director
    21,242 2022-05-19 1

    SCHWARTZ JEFFREY LAWRENCE

    • Director
    4,852,549 2022-05-19 1

    PERIER FRANCIS I JR CHIEF FINANCIAL OFFICER

    • Officer
    27,502 2022-01-07 3

    WEINSTEIN HERSCHEL S GENERAL COUNSEL & SECRETARY

    • Officer
    18,739 2022-01-07 3

    ISLAM SAQIB CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    851,695 2022-01-07 5

    NOFI MICHAEL CHIEF ACCOUNTING OFFICER

    • Officer
    8,181 2022-01-07 3

    EDRIS BADREDDIN CHIEF OPERATING OFFICER

    • Officer
    325,813 2022-01-07 3

    PICHL DANIEL CHIEF PEOPLE OFFICER

    • Officer
    21,456 2022-01-07 3

    ASHAR BHAVESH CHIEF COMMERCIAL OFFICER

    • Officer
    66,272 2022-01-06 1

    BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC

    BC SW, LP

    SCHWARTZ JEFFREY LAWRENCE

    KOPPEL ADAM

    • Director
    • 10% Owner
    4,832,413 2021-08-10 0

    RENSTRUP JENS CHIEF MEDICAL OFFICER

    • Officer
    250,499 2021-01-07 0

    PFIZER INC

    PFIZER VENTURES (US) LLC

    • 10% Owner
    4,593,847 2019-09-17 0

    HORN ANDRE R

    • Director
    24,000 2009-05-19 0

    PFEFFER MATTHEW J

    • Director
    0 2009-01-06 0

    SALAS PETER E

    • Director
    20,000 2007-03-01 0

    NEEDHAM & CO LLC

    NEEDHAM GEORGE A

    • 10% Owner
    10,627,446 2006-08-23 0

    NEEDHAM GROUP, INC.

    • 10% Owner
    2,009,807 2006-08-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    ORBIMED ADVISORS LLC - > 10% Owner see footnotes

    ORBIMED CAPITAL GP VI LLC - > 10% Owner see footnotes

    2022-09-14 16:24:34 -0400 2022-09-12 S 123,897 $31.96 d 5,629,842 indirect -7.6266 -14.0368 0.0 1 -14.2998 5

    ORBIMED ADVISORS LLC - > 10% Owner see footnotes

    ORBIMED CAPITAL GP VI LLC - > 10% Owner see footnotes

    2022-09-14 16:24:34 -0400 2022-09-12 S 30,000 $31.98 d 5,599,842 indirect -7.6266 -14.0368 0.0 1 -14.2998 5

    ORBIMED ADVISORS LLC - > 10% Owner see footnotes

    ORBIMED CAPITAL GP VI LLC - > 10% Owner see footnotes

    2022-08-10 16:22:01 -0400 2022-08-09 S 69,568 $37.47 d 5,753,739 indirect 3.2909 -2.8309 -11.5357 13.1635 22 -11.5357 31

    ORBIMED ADVISORS LLC - > 10% Owner see footnotes

    ORBIMED CAPITAL GP VI LLC - > 10% Owner see footnotes

    2022-08-10 16:22:01 -0400 2022-08-08 S 205,000 $38.33 d 5,823,307 indirect 3.2909 -2.8309 -11.5357 13.1635 22 -11.5357 31

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 22:15:04 UTC 2.7595 0.3105 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 21:45:03 UTC 2.7595 0.3105 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 21:15:03 UTC 2.7595 0.3105 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 20:45:04 UTC 2.7595 0.3105 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 20:15:03 UTC 2.7595 0.3105 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 19:45:03 UTC 2.7595 0.3105 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 19:15:03 UTC 2.7595 0.3105 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 18:45:03 UTC 2.7827 0.2873 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 18:15:04 UTC 2.7827 0.2873 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 17:45:04 UTC 2.7827 0.2873 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 17:15:03 UTC 2.7827 0.2873 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 16:45:04 UTC 2.7874 0.2826 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 16:15:03 UTC 2.7874 0.2826 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 15:45:03 UTC 2.7874 0.2826 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 15:15:03 UTC 2.7874 0.2826 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 14:45:03 UTC 2.7874 0.2826 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 14:15:03 UTC 2.7874 0.2826 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 13:45:03 UTC 2.5861 0.4839 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 13:15:03 UTC 2.5861 0.4839 300000
    SPRINGWORKS THERAPEUTICS INC SWTX 2022-09-30 12:45:03 UTC 2.5861 0.4839 55000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund SWTX -7.0 shares, $-189.0 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund SWTX -6.0 shares, $-162.0 2020-03-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity Fund SWTX -370.0 shares, $-26584.5 2021-11-30 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity ETF SWTX -1424.0 shares, $-26970.56 2022-05-31 N-PORT
    VANGUARD MONTGOMERY FUNDS- VANGUARD MARKET NEUTRAL FUND SWTX -50108.0 shares, $-1233658.96 2022-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments